HSPB2 and neoplasm: Focusing on superficial tumors (TaT1), decreased HSPB2 and HSPB3 mRNA levels were correlated with a significantly higher risk for disease recurrence following TURBT, independently of tumor stage, grade, EORTC-risk group, and gender.